Zydus gains USFDA approval for Verapamil Hydrochloride extended-release tablets

Zydus Lifesciences Limited has received final approval from the USFDA for its Verapamil Hydrochloride Extended-Release Tablets USP, in 120 mg, 180 mg, and 240 mg dosages. These tablets, used to manage high blood pressure and reduce the risk of serious heart problems, will be manufactured at the company's facility in Baddi, Himachal Pradesh.

The approved drug had annual sales of $24.5 million in the United States as of September 2025, according to IQVIA MAT data. This approval contributes to Zydus's growing portfolio, bringing their total approvals to 428.

Since initiating its filing process in fiscal year 2003-04, Zydus has submitted 487 Abbreviated New Drug Applications (ANDAs) as of September 30, 2025.